Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Group 1 - Pfizer is acquiring Metsera for $4.9 billion, paying $47.50 per share, which is a premium of over 42% compared to Metsera's closing price on Friday [1] - Pfizer may pay an additional $22.50 per share based on the development of Metsera's product pipeline [1] - Metsera has no products on the market but has four programs in clinical development and one in mid-stage testing [2] Group 2 - Demand for obesity treatments has increased significantly, driven by leading products like Zepbound from Eli Lilly and Wegovy from Novo Nordisk [2] - Pfizer currently has no obesity treatments available but is working on some in clinical development [3] - Earlier in the year, Pfizer halted the development of a potential once-daily pill treatment before late-stage testing [3]